Biogenstar CTF Perfusion Control Platform
| Brand | Biogenstar |
|---|---|
| Origin | Shanghai, China |
| Manufacturer Type | Direct Manufacturer |
| Regional Classification | Domestic (China) |
| Model | CTF |
| Pricing | Available Upon Request |
Overview
The Biogenstar CTF Perfusion Control Platform is an integrated, software-driven bioprocessing system engineered for continuous perfusion culture of mammalian and immune cells in bioreactors ranging from 1 L to 5 L working volume. It operates on the principle of tangential flow filtration (TFF), utilizing a dual-loop TFF architecture to achieve high-efficiency cell retention with minimal shear stress and low product hold-up. Unlike conventional dead-end or single-loop filtration systems, the CTF platform employs a precisely balanced recirculation loop—comprising a low-shear pulsatile peristaltic pump, modular filtration cassettes, and real-time mass-based feedback—to maintain stable viable cell densities (>20 × 10⁶ cells/mL) over extended durations (≥30 days). Its design adheres to fundamental bioreactor process control theory: maintaining constant viable cell concentration while decoupling nutrient supply, waste removal, and product harvest through independent flow regulation. This enables robust process intensification for upstream biomanufacturing without compromising cell viability or product quality attributes.
Key Features
- Low-Shear Pulsatile Pump Technology: Patented linear-flow peristaltic pump with programmable pulse modulation minimizes transient shear peaks (<0.5 Pa) — validated for sensitive cell lines including CHO-K1, HEK293, primary NK cells, and activated T lymphocytes.
- Dual-Loop Tangential Flow Filtration: Independent feed and retentate recirculation loops ensure uniform crossflow velocity across the membrane surface, reducing concentration polarization and fouling — resulting in consistent separation efficiency and <5% cell loss per cycle.
- Modular & Open Architecture: Physical separation of pump module and filtration unit allows interchangeable integration with flat-sheet, hollow-fiber, or spiral-wound cassettes (0.1–0.65 µm pore size; PVDF, PES, or regenerated cellulose membranes).
- Integrated Mass-Based Control Logic: High-precision load cells (±0.1 g resolution) monitor bioreactor weight in real time; software dynamically adjusts perfusion rate, bleed volume, and feed addition to maintain target culture volume and metabolite balance.
- Scalable Process Design: CTF platform supports geometric and kinetic similarity scaling — validated correlation between lab-scale (1 L) and pilot-scale (5 L) operation demonstrates ≤12% deviation in VCD trajectory, glucose consumption rate, and lactate yield.
Sample Compatibility & Compliance
The CTF platform accommodates suspension-adapted mammalian cell lines (CHO, SP2/0, NS0), human primary immune cells (CAR-T, NK, dendritic cells), and viral vector producer lines (HEK293T, Sf9). All wetted materials comply with USP Class VI biological safety standards and meet ISO 10993-5 cytotoxicity requirements. The system architecture supports ALCOA+ data integrity principles: audit trails record all parameter changes, user actions, and alarm events with timestamped, non-erasable entries. Software functionality aligns with FDA 21 CFR Part 11 requirements for electronic records and signatures when deployed with appropriate validation protocols and role-based access controls.
Software & Data Management
The proprietary CTF Control Suite provides intuitive graphical configuration of perfusion strategies — including constant-volume, exponential-feed, or metabolite-triggered modes. All control algorithms operate on closed-loop PID logic with configurable setpoints and hysteresis bands. Raw sensor data (weight, pump speed, temperature, pH, DO) are logged at 1 Hz and exported in CSV or HDF5 format. Built-in trend analysis tools enable real-time overlay of VCD, viability, glucose, lactate, and product titer — facilitating rapid process understanding and deviation investigation. Data export conforms to ISA-88/ISA-95 batch record structures for seamless integration into MES or QMS platforms.
Applications
The CTF platform serves critical roles across biopharmaceutical development lifecycles: early-stage process characterization of monoclonal antibodies and Fc-fusion proteins; optimization of lentiviral and AAV vector production titers; scalable expansion protocols for autologous and allogeneic cell therapies; and commercial manufacturing support for vaccine candidates requiring high-yield, low-aggregate upstream processing. It is routinely deployed in GLP-compliant cell line development labs and GMP-aligned pilot facilities conducting tech transfer to 200–2000 L bioreactor trains.
FAQ
Can the CTF platform be integrated with third-party bioreactors?
Yes — it features standard 4–20 mA analog I/O and Modbus TCP communication interfaces compatible with major bioreactor vendors (e.g., Sartorius, Eppendorf, Applikon, and Thermo Fisher).
Does the system support automated harvest cycles?
Yes — the software includes configurable harvest triggers based on accumulated product mass, culture duration, or offline assay results (via manual entry or API integration).
What filtration membranes are validated for use with the CTF platform?
Biogenstar provides qualification reports for Pall Acrodisc® SF, Sartorius Sartobran® P, and Repligen KrosFlo® KR2i cassettes — full compatibility documentation available under NDA.
Is remote monitoring supported?
Yes — optional secure cloud gateway enables encrypted remote access to live trends, alarms, and historical logs via web browser or mobile application (TLS 1.2+, OAuth 2.0 authentication).
What validation support is provided for GMP implementation?
Biogenstar delivers IQ/OQ protocol templates, FAT/SAT test scripts, and traceability matrices aligned with ASTM E2500 and Annex 11 expectations — delivered with system commissioning.
